Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey.

Authors:
Evans M; de Courcy J; de Laguiche E; Faurby M; Haase CL and 3 more

Journal:
Int J Obes (Lond)

Publication Year: 2023

DOI:
10.1038/s41366-023-01325-1

PMCID:
PMC10359184

PMID:
37258646

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Int J Obes (Lond)

Abbreviation: Int J Obes (Lond)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Clinical characteristics and outcomes of children, adolescents and young adults with overweight or …
Galler A; Thönnes A; Joas J and 12 more (2024) - Transparency Score: 3/6
Acute and long-term exercise adaptation of adipose tissue and skeletal muscle in humans: a matched …
Dreher SI; Irmler M; Pivovarova-Ramich O and 14 more (2023) - Transparency Score: 5/6
A meta-analysis on the changes of BMI during an inpatient treatment with different follow-up length…
Rondanelli M; Gasparri C; Rigon C and 7 more (2023) - Transparency Score: 2/6
Anthropometric estimators of abdominal fat volume in adults with overweight and obesity.
Michel S; Linder N; Linder A and 6 more (2023) - Transparency Score: 3/6
A role of STING signaling in obesity-induced lung inflammation.
Qi Y; Wu Z; Chen D and 2 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests ME has received fees from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. JdC and AM are employees of Adelphi, which received consulting fees from Novo Nordisk A/S to perform this analysis. EdL, MF, CLH and KSM are employees of Novo Nordisk A/S. JP-S is partner and Head of Health Analytics at Lane Clark & Peacock LLP and Chair-elect of the Royal Society for Public Health, and reports personal fees from Novo Nordisk A/S and Pfizer Ltd outside of the submitted work."

Evidence found in paper:

"This study was funded by Novo Nordisk A/S. Medical writing support was provided by Caroline Freeman, PhD of Oxford PharmaGenesis, Oxford, UK, and funded by Novo Nordisk A/S."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025